Table 2 Baseline characteristics of the individual case safety reports concerning immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis
Characteristic | Patients No. (%) (n = 38) |
|---|---|
Age | |
Reported | 33 (87) |
Median [IQR], years | 63 [45–72] |
Not reported | 5 (13) |
Sex | |
Male | 29 (76) |
Female | 9 (24) |
Cancer type | |
Melanoma | 21 (55) |
Lung cancer | 5 (13) |
Bladder cancer | 3 (8) |
Renal cell carcinoma | 2 (5) |
Hodgkin disease | 1 (3) |
Transitional cell carcinoma | 1 (3) |
Adenocarcinoma gastric | 1 (3) |
Thymoma | 1 (3) |
T cell lymphoblastic leukemia acute | 1 (3) |
Not reported | 2 (5) |
Co-suspected drugs | |
Reported | 4 (10) |
Antineoplastic agents | 2 (5) |
Antibacterial agents | 2 (5) |
Not reported | 34 (90) |
Drugs | |
Anti-CTLA-4 (ipilimumab) monotherapy | 7 (18) |
Anti-PD-1 monotherapy | |
nivolumab | 14 (37) |
pembrolizumab | 7 (18) |
Anti-PD-L1 monotherapy | |
Atezolizumab | 1 (3) |
ipilimumab and nivolumab combination therapy | 5 (13) |
nivolumab and ipilimumab sequential therapy | 3 (8) |
pembrolizumab and ipilimumab sequential therapy | 1 (3) |
Reporting | |
2014 | 1 (3) |
2015 | 3 (8) |
2016 | 6 (16) |
2017 | 10 (26) |
2018 | 18 (47) |